Guidelines & Consensus
Women's Attitudes toward the 2024 US Preventive Services Task Force Mammography Screening Guideline
Yoder et alMedical Decision Making
In 2024, the US Preventive Services Task Force (USPSTF) updated its breast cancer screening recommendations from individualized, informed decision-making for women aged 40 to 49 years to routine biennial screening for women aged 40 to 74 years. Because the empirical evidence regarding the balance of screening benefits and harms changed minimally from earlier estimates, investigators conducted a randomized experiment to evaluate women's perceptions of this guideline change and determine whether disclosing the static nature of the underlying evidence altered their views.
The study surveyed 301 women aged 39 to 49 years (mean age 43.3 ± 2.9 years; 68.4% White, 9.0% Hispanic) without a history of breast cancer who had previously engaged with a mammography decision aid. Following the guideline release, participants were randomized to receive either basic details regarding the new guideline or the basic announcement paired with explicit communication about the updated benefit-and-harm data. Evaluated endpoints included attitudes toward the guideline, trust in the USPSTF, and perceived mammography benefits and harms.
The randomized intervention showed that presenting updated evidence on benefits and harms had no statistically significant impact on any measured outcome (all p > 0.05). Overall, women evaluated the updated recommendation favorably, with 61% expressing positive or very positive attitudes. Participants demonstrated moderately high trust in the USPSTF (mean 5.57 ± 1.00 on a 1–7 scale), perceived high screening benefit (mean 4.34 ± 0.80 on a 1–5 scale), and anticipated low harm (mean 1.81 ± 0.73 on a 1–5 scale). Observed variations in opinion regarding how often to screen suggest that screening intervals remain preference-sensitive in clinical practice.
Key Takeaways
- Among women aged 39 to 49 years, 61% viewed the 2024 USPSTF mammography guideline positively or very positively, with participants reporting high perceived screening benefit (mean 4.34 on a 1–5 scale) and low perceived harm (mean 1.81 on a 1–5 scale).
- Providing updated data showing that evidence for screening benefits and harms had changed very little from past estimates had no significant effect on participant attitudes, trust in the USPSTF, or risk-benefit perceptions (all p > 0.05).
- Trust in the USPSTF remained moderately high following the update (mean 5.57 on a 1–7 scale), while divergent opinions regarding screening frequency indicated that mammography intervals remain preference-sensitive.
Read the original sourceMedical Decision Making
